NCT00184366

Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis

Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 96 (actual)
• Sponsor: Norwegian University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objectives of the project are: * To classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in Psoriasis Area and severity Index (PASI), Psoriasis Disability Index 8PDI) and dermatology Life Quality Index 8 DLQI) * To characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab.

Detailed description

This is an investigator initiated,prospective, longitudinal, observation study. Before starting treatment with efalizumab we will record factors such as demographic data, type of psoriasis, previous treatment, other diseases etc. We will follow the patients and classify them as responders and non-responders. We hope to find 4-5 factors which we can use later to predict response of this drug.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	efalizumab	efalizumab

Timeline

• Start date: 2005-05-01
• Primary completion: 2008-05-01
• Completion: 2008-07-01
• First posted: 2005-09-16
• Last updated: 2012-01-19

Locations

1 site across 1 country: Norway